JAVASCRIPT DISABLED - This site works best with JavaScript enabled.

Mast Launches New Carbapenemase Detection Set

Mast is pleased to announce the launch of a NEW Carbapenemase Detection Set, the latest innovative product in its hugely successful Antibiotic Resistance Detection Set portfolio.

The emergence and dissemination of carbapenem-hydrolysing Ss-lactamase enzymes over the last decade poses a serious threat to public healthcare. Of special concern is the broad spectrum of resistance harboured by carbapenemase producing Enterobacteriaceae, severely limiting therapeutic options. Accordingly, there remains a need to rapidly identify carbapenemase producers to guide appropriate antibiotic usage, and prevent the development of outbreaks¹.

Mast's Carbapenemase Detection Set provides a reliable phenotypic identification of metallo Ss-lactamases (MBL) and Klebsiella pneumoniae carbapenemases (KPC), with 100% sensitivity for NDM-1, whilst differentiating KPC positive isolates from those expressing ampC coupled with porin loss.

Minimum inhibitory concentrations (MICs) are notoriously variable in carbapenemase producing isolates², further supporting David Livermore's argument that it is invaluable to directly seek carbapenemases to deliver effective antibiotic management policies.

Using a combination disc technology incorporating specific enzyme inhibitors to positively detect resistant enzymes, discs are manufactured as 'matched pairs' to prevent erroneous results arising from variation in content providing a comprehensive, reliable and cost-effective test.

This simple 4-disc system is available in a convenient cartridge format, compatible with any Mast DiscMaster dispenser, streamlining work flow and assisting smooth integration into routine laboratory testing.

References:

Nordmann, P., Poirel, L. Strategies for identification of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2013 68: 487-489

Livermore, D.M., Andrews, J.M., Hawkey, P.M., Ho, P.L., Keness, Y., Doi, Y.. et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother. 2012;67:1569-77

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Mast Group Ltd. View Company Information

Posted on March 11, 2013